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Abstract 
Post-transplant lymphoproliferative disorders 
(PTLDs) are serious, life-threatening complications 
of transplantation, which represent a heterogeneous 
group of lymphoproliferative diseases and show a 
spectrum of clinical, morphologic, and molecular 
genetic features ranging from reactive polyclonal 
lesions to frank lymphomas. Florid follicular 
hyperplasia (FFH) PTLD is a kind of early lesions, 
which shows characteristic clinicopathological 
features and molecular involvement. 
Clinics and pathology 
Disease 
The term "post-transplant lymphoproliferative 
disorder" or disease (PTLD) was first introduced in 
1984 by Starzl (Starzl et al., 1984) .PTLDs are 
serious, life-threatening complications of solid-
organ transplantation (SOT) and bone marrow 
transplantation, and are associated with high 
mortality. PTLDs represent a heterogeneous group 
of lymphoproliferative diseases, which show a 
spectrum of clinical, morphologic, and molecular 
genetic features ranging from reactive polyclonal 
lesions to frank lymphomas. 
PTLDs are classified into early lesions, 
polymorphic, monomorphic and classical Hodgkin's 
lymphoma-like PTLD. 
FFH PTLD is a kind of early lesions, which shows 
characteristic clinicopathological features and 
molecular involvement. The early lesions are 
defined as lymphoid proliferations in an allograft 
recipient, characterized by architectural preservation 
of the involved tissue, with preservation of the nodal 
sinuses or tonsillar crypts, and residual or sometimes 
floridly reactive follicles in some cases. FFH PTLD 
is defined as a distinct entity in 2016 WHO 
classification of lymphoid neoplasms. Such lesions, 
although reactive, may have clonal chromosomal 
abnormalities and may lead to uncontrolled 
lymphoid proliferation in solid organ transplant 
recipients. (Swerdlow, et al ,2008. Mucha, et al. 
2010. Swerdlow, et al, 2016. Vakiani, et al, 2007). 
Phenotype/cell stem origin 
The majority (>90%) of PTLD in solid organ 
recipients are of host origin and only a minority of 
donor origin. Donor origin PTLD appear to be most 
common in liver and lung allograft recipients, and 
frequently involve the allograft. In contrast, the 
majority of PTLD in bone marrow(BM) allograft 
recipients are of donor origin, as would be expected, 
since successful engraftment results in an immune 
system that is nearly exclusively of donor origin 
(Chadbum, et al ,1995. Swerdlow, et al, 2008). 
Phenotypically, FFH PTLD cases show follicular 
hyperplasia and the size of the follicles varied, but 
they all contained large, polarized, germinal centers 
with many mitoses and mantle zones that were often 
attenuated. Some cases of FFH may lack increased 
numbers of plasma cells. Some cells of which may 
express CD20, PAX5, CD3, CD5 , with markedly 
enlarged germinal centers (CD10+, BCL6+, BCL2-) 
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containing numerous tingible-body macrophages 
and expanded follicular dendritic cell meshworks 
(CD21+). EBV detected by in situ hybridization is 
usually positive, and the number of EBV-positive 
cells are usually fewer, but some cases of FFH may 
be EBV negative (Swerdlow, et al, 2008. Vakiani, et 
al, 2007). 
Epidemiology 
The incidence of PTLD ranges from 1-3 % in renal 
to 5-20 % in lung and intestinal transplantation, 
related to the type of transplanted organ, intensity of 
IS, age, and viral infection, etc (Opelz, 2003. Opelz, 
1993). In contrast, the incidence of PTLD after BMT 
is about 1.0 % for recipients from HLA-compatible 
related donors (lower than that of SOT), but in up to 
25 % for high-risk patients (Curtis, 1999). However, 
the field has evolved during the last decade. Hoegh-
Petersen et al. found a frequency of 8.1 % among 307 
allo-HSCT recipients who had also received ATG-
based conditioning. Kamani et al. found an overall 
incidence of 2.3 % for post-transplant malignancy 
(most of which were PTLD) in patients receiving 
such transplant for primary immunodeficiency 
disorders. The highest subgroup, those patients with 
Wiskott-Aldrich syndrome, had a 3.3 % frequency. 
In our hospital, it is 1.5 % (9/585) from August 2002 
to October 2006 and about 1 % (9/857) from 
November 2006 to November 2009 after allo-HSCT, 
respectively. The incidence of PTLD was higher in 
mismatched or unrelated HSCT group than that of 
conventional one, 3.4 % (7/208), 2.3 % (1/44) versus 
0/323. It was also higher in patients with 
conditioning regimen including ATG than those 
without, 3.4 % (9/262) vs. 0/323. FFH PTLD 
accouted for 4 of 15 cases in a study of eraly lesions 
of PTLD. (Swerdlow et al, 2008. Chen, 2013. Nelson 
et al, 2012). 
Clinics 
The clinical features of PTLD differ from those of 
lymphomas observed in the general population. 
Symptoms may be mild, such as fever, 
mononucleosis-like syndrome, lymphadenopathy, 
recurrent infections or severe organ dysfunction. The 
variable manifestation of PTLD depends on many 
factors, such as the type of transplanted organ or IS 
used, histopathology and time elapsed since 
transplantation. The first year after transplantation is 
important, in lung recipients, more than 50 % of all 
PTLDs develop during the first post-transplant year. 
Our data showed that 88.2 % of patients (15/17) were 
diagnosed within 7 months after transplantation (1.5-
7 months), and the median interval after 
transplantation to the diagnosis was 2.5 months 
(mean 4.7 months, range 1.5-19 months), shorter 
than that of SOT. The frequent sites of PTLD include 
GI (jejunum more often than colon), lymph nodes, 
and central nervous system, different from type to 
type of transplantation. 
Early lesions mostly develop within 1 year after 
transplantation, and most patients with early lesions 
affected tonsils, Waldeyer ring, adenoids or lymph 
nodes, of which FFH PTLD often affects 
adenotonsillar, nodal, and extranodal lymphoid 
tissue.They often show spontaneous regression or 
regress following reduction in IS, and express EBER 
or EBV-LMP-1 (Opelz, 2003. Swerdlow, et al, 2008. 
Johnson, 2006. Vakiani et al, 2007). 
Pathology 
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Figure 1.  Florid follicular hyperplasia in tonsil. Many variably sized reactive follicles (H&E staining). 
(reproduced with permission from Hum Pathol. Vakiani E, Nandula SV, Subramaniyam S, et al. Cytogenetic 
analysis of B-cell posttransplant lymphoproliferations validates the World Health Organization classification and 
suggests inclusion of florid follicular hyperplasia as a precursor lesion. Hum Pathol. 2007;38:315-325). 
 
 
The underlying lymph node and extranodal sites( 
tonsils and adenoids) diagnosed as FFH PTLD show 
markedly enlarged germinal centers (CD10+, 
BCL6+, BCL2-) containing numerous tingible-body 
macrophages and expanded follicular dendritic cell 
meshworks (CD21+). A variable number of follicles 
showed blurring of the dark zone-light zone 
boundary and attenuation or loss of the mantle zones. 
Interfollicular areas were only mildly expanded by 
small lymphocytes, scattered immunoblasts, and 
small clusters of polytypic plasma cells 
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Figure 2.  Florid follicular hyperplasia in tonsil. In situ hybridization withEpstein-Barr virus (EBV)-encoded 
RNA shows EBV-positive cells that are more numerous in a germinal center with occasional positive cells 
among the follicles (H&E staining). (From Vakiani E, Nandula SV, Subramaniyam S, et al. Cytogenetic analysis 
of B-cell posttransplant lymphoproliferations validates the World Health Organization classification and 
suggests inclusion of florid follicular hyperplasia as a precursor lesion. Hum Pathol. 2007;38:315-325). 
 
Treatment 
There is no consensus on the optimal treatment of 
PTLD. It is generally agreed that three major 
strategies should be applied: restoration of the 
recipient's immunity (to limit the EBV infection), 
elimination EBV and removal of neoplastic B cells. 
Reduction of IS or even withdrawal remains the first-
line treatment. With reduction of IS, virtually all 
early lesions regress and generally show good 
prognosis, whereas half of P-PTLD regress and some 
will progress, the majority of M-PTLDs do not 
regress . DLI was effectively used in EBV-
associated PTLD after mismatched/haploidentical 
haematopoietic stem cell transplantation (HSCT). 
Patients with lymph node localization have a 
relatively good outcome, and disseminated disease 
in contrast has a poor prognosis (Mucha ,2010. Xu, 
2010). 
Prognosis 
The prognosis of PTLD is poor. The treatment of 
rejection episodes with OKT3 or ATG enhances the 
PTLD risk in patients who did not receive antibody 
induction, rejection therapy with OKT3 or ATG adds 
to the already increased lymphoma risk HLA 
matching is also a risk factor in the pathogenesis of 
PTLD, and HLA-B or HLA-DR mismatches 
especially seem to be critical. The number of HLA 
mismatches parallels with an increased risk of 
PTLD. The indolent behavior of early lesion of 
PTLD in a series and others may be related in part to 
the fact that they are almost always polyclonal and 
do not harbor alteration of oncogenes or tumor 
suppressor genes. Although clonal cytogenetic 
abnormalities have been rarely detected in FFH 
TLDs, they have also had good clinical outcome 
without aggressive therapy. In a study, two patients 
had adenotonsillar FFH PTLD, and one patient 
developed M-PTLD involving tonsils and adenoids, 
8.5 years after PH at the same site (Opelz,2003. 
Opelz,2010. Vakiani,et al, 2007). 
Genetics 
N 
In a study, polymerase chain reaction analysis of the 
IGH gene found germline configuration in FFH 
PTLD. Clonal karyotypic abnormalities were 
detected in 2 (11.1%) of 18 FFH PTLD, and 
recurrent chromosome breaks at 1q11-21,14q32 
were identified. (Vakiani, et al, 2007). Increased 
mTOR signaling in FFH PTLD suggests that this 
may be an early feature of the lymphoproliferative 
process in the posttransplant setting (Nelson, et al, 
2012). 
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